Trafficking of CD34+ cells into the peripheral circulation during collection of peripheral blood stem cells by apheresis.
The number of CD34+ cells collected during apheresis is related to the volume of blood processed. In large-volume apheresis (LVL) procedure, more cells can be collected than were originally present in the peripheral blood at the start of the collection procedure. We prospectively studied the levels of CD34+ cells in the blood and apheresis product during LVL procedures for 21 patients with acute myelogenous leukemia or multiple myeloma. These patients experienced a slow decline in blood CD34+ cell concentrations during the apheresis procedure. No patient demonstrated a sustained rise in CD34+ cell counts as a result of the procedure. The number of CD34+ cells collected exceeded the number calculated to be in the peripheral blood at the start of the procedure by an average of 3.0-fold. The efficiency of collection for CD34+ cells averaged 92.6% and did not vary with speed of blood processing, diagnosis, or mobilization regimen. The calculated release of CD34+ cells from other reservoirs into the peripheral blood averaged 3.71 x 10(6)/min (range, 0.36-13.7 x 10(6)/min), and correlated (r = 0.82) with the concentration of these cells in the peripheral blood at the start of the procedure. These data show that the apheresis procedure used in this study does not affect the release of CD34+ cells in a cytokine-treated patient. LVL will result in collection of larger quantities of CD34+ cells than procedures involving processing of smaller volumes of blood, but the number of cells collected is limited by the rate of release of these cells into the peripheral circulation where they are accessible for collection.
Rowley
S D
SD
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Yu
J
J
Gooley
T
T
Heimfeld
S
S
Holmberg
L
L
Maloney
D
D
Bensinger
W I
WI
D000208:Acute Disease; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D001772:Blood Cell Count; D001781:Blood Component Removal / Q000379:methods*; D001792:Blood Platelets / Q000166:cytology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D005047:Etoposide / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology; D006098:Granulocytes / Q000166:cytology; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology; D009101:Multiple Myeloma / Q000097:blood / Q000628:therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology; D011446:Prospective Studies; D011994:Recombinant Proteins; D014182:Transplantation, Autologous
D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C081222:sargramostim; D005047:Etoposide; D003907:Dexamethasone; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D017239:Paclitaxel; D000069585:Filgrastim